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Abstract
Proteins routed to the secretory pathway start their journey by being transported across biological membranes, such as the 
endoplasmic reticulum. The essential nature of this protein translocation process has led to the evolution of several factors 
that specifically target the translocon and block translocation. In this review, various translocation pathways are discussed 
together with known inhibitors of translocation. Properties of signal peptide-specific systems are highlighted for the devel-
opment of new therapeutic and antimicrobial applications, as compounds can target signal peptides from either host cells or 
pathogens and thereby selectively prevent translocation of those specific proteins. Broad inhibition of translocation is also 
an interesting target for the development of new anticancer drugs because cancer cells heavily depend on efficient protein 
translocation into the endoplasmic reticulum to support their fast growth.
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BiP  Binding immunoglobulin protein
CADA  Cyclotriazadisulfonamide
CaM  Calmodulin
CRF-R-1  Corticotropin-releasing factor receptor 1
ER  Endoplasmic reticulum
ERAD  Endoplasmic reticulum-associated protein 
degradation
ESI  Eeyarestatin I
GET  Guided entry of tail-anchored proteins
GPI  Glycosylphosphatidylinositol
hCD4  Human CD4
HHV-7  Human herpes virus-7
HIV  Human immunodeficiency virus
Hsc70  Heat shock cognate 70
Hsp70  Heat shock protein 70
ICAM-1  Intercellular adhesion molecule 1
NC  Nascent chain
OST  Oligosaccharyl-transferase complex
PMF  Proton motive force
ppαF  Pre-pro-α-factor
prl  Protein localization
PrP  Prion protein
RNC  Ribosome-nascent chain complex
SA  Signal anchor
SND  SRP-independent targeting
SP  Signal peptide
SPC  Signal peptidase complex
SR  SRP receptor
SRP  Signal recognition particle
SSP  Small secreted protein
TA  Tail-anchored membrane protein
TMD  Transmembrane domain
TNFα  Tumor necrosis factor alpha
TRAM  Translocating chain-associated membrane 
protein
TRAP  Translocon-associated protein
TRC  Transmembrane domain recognition complex
UPR  Unfolded protein response
VCAM  Vascular cell adhesion molecule
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Different signal peptide‑dependent 
translocation pathways
More than 30% of all human genes encode proteins des-
tined for the extracellular environment, cell membrane or 
components of the secretory pathway [1]. Since protein 
synthesis occurs in the cytosol, translocation of proteins 
across biological membranes is essential for cellular 
function. Multiple pathways of protein translocation have 
been proposed. In general, translocation from the cyto-
sol requires three key steps: (1) substrate recognition and 
targeting to the destination membrane, while maintaining 
the substrate in a translocation-competent state (2) trans-
location across or integration into that membrane, which 
usually requires energy expenditure in the form of GTP, 
ATP or proton motive force and (3) release, folding and 
maturation of the protein substrate.
Targeting signals contain the principal information that 
drives protein translocation. They direct newly synthesized 
proteins to their target membrane for translocation or 
membrane integration [2]. Signals present at the N-termi-
nus of the synthesized protein are termed signal peptides 
(SP) or signal sequences. SPs are cleaved from the mature 
protein after translocation by the signal peptidase com-
plex (SPC) and are characterized by a short (8–12 amino 
acids) hydrophobic segment, but their length and amino 
acid composition are highly divergent [3, 4]. Alternatively, 
targeting is facilitated by uncleaved amino-terminal sig-
nals termed signal anchors (SA). Signal anchors can act 
as a transmembrane segment and usually contain about 
20 (or more) hydrophobic residues, a length required to 
physically span the approximately 3 nm wide hydrophobic 
interior of the phospholipid bilayer in an α-helical fold [5]. 
A third distinction is made for a class of proteins called 
tail-anchored membrane proteins (TA proteins), which 
have a single hydrophobic transmembrane region at their 
C-terminus that acts both as a targeting signal and mem-
brane anchor [6].
The conserved Sec-dependent pathway is used for the 
translocation of most eukaryotic proteins [7]. The cen-
tral component of this system is the heterotrimeric Sec61 
translocon complex, also known as the SecY complex in 
bacteria and archaea [8]. It forms an aqueous channel in 
the endoplasmic reticulum (ER) membrane which allows 
protein transport across the membrane and it facilitates 
insertion of hydrophobic protein segments into the lipid 
bilayer. The Sec pathway operates in two major modes of 
translocation: (1) co-translational translocation couples 
the ribosomal protein synthesis directly to translocation 
through the channel, which efficiently uses the energy from 
mRNA translation in ribosomes to drive protein translo-
cation across the membrane, (2) while post-translational 
translocation delivers completely synthesized polypeptide 
chains to the membrane which is best understood in fungi 
and bacteria. Mitochondrial, chloroplast and peroxisomal 
protein import, as well as specialized bacterial secretion 
systems (suggested reviews: [9–12]) are not discussed 
here, but the general concepts of signal peptide-dependent 
translocation (use of targeting signals and specialized pro-
tein-conducting channels) are conserved in these systems.
Co‑translational translocation
The process of co-translational translocation is a multistep 
sequence that depends on dynamic interactions between 
many factors. For most of these steps, natural and synthetic 
inhibitors have been discovered that usually affect transloca-
tion of a broad range of co-translational substrates. However, 
some compounds are able to operate in a signal peptide-
selective way.
Synthesis of proteins destined for the co-translational 
pathway starts with mRNA translation in cytosolic ribo-
somes (Fig. 1). Once the hydrophobic targeting signal of 
the nascent chain (NC) emerges from the ribosomal exit 
tunnel, it is recognized by the signal recognition particle 
(SRP), a universally conserved ribonucleoprotein complex 
[13]. The S-domain contains the evolutionarily conserved 
SRP54 subunit that binds signal peptides, functions as a 
GTPase and interacts with the membrane-associated SRP 
receptor (SR). Eukaryotic SRP has an additional Alu domain 
that forms an elongated, kinked structure. After recognition 
of the signal by the S-domain, the Alu domain reaches into 
the elongation factor binding site of the ribosome [13] and 
slows down elongation of the polypeptide chain. The SRP 
and ribosome-nascent chain complex (RNC) is then targeted 
to the ER membrane where SRP binds the SRP receptor 
(SR). The current model of SRP function suggests that this 
mechanism maintains the RNC in a translocation-competent 
state during the targeting step and GTP-dependent transfer of 
the RNC to the translocon [14, 15]. The Sec61/SecY trans-
locon forms a passive pore in the ER membrane (or plasma 
membrane in bacteria) where the targeting signal needs to be 
recognized a second time. After successful recognition and 
opening of the pore, the polypeptide is finally translocated 
across or embedded into the membrane.
The Sec translocon is a dynamic protein complex
The Sec61 complex consists of a central Sec61α subunit 
(referred to as SecY in bacteria and archaea) which forms 
the channel, and two smaller peripheral subunits Sec61β and 
Sec61γ [8]. Sec61γ is homologous to SecE in bacteria and 
archaea, but Sec61β shows little homology to the bacterial 
SecG subunit. Sec61α contains ten transmembrane helices 
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divided into two halves of the channel (TM 1-5 and TM 
6-10) with a hinge point between TM helix 5 and 6, often 
referred to as a ‘clam shell’ design. The ‘lateral gate’ of 
Sec61α, formed by the interface of transmembrane helices 
2 and 7, allows opening of the channel towards the lipid 
bilayer for lipid insertion of transmembrane domains [16]. It 
also serves as the recognition site of signal peptides [17] and 
allows hydrophobic peptide region access to the lipid layer 
[18]. The inside of the channel is hourglass-shaped, with a 
ring at the center consisting of six bulky hydrophobic amino 
acid residues (the pore ring) which position their side chains 
to the center of the pore. This ring prevents leakage of ions 
through the inactive channel and during translocation of a 
protein substrate. The lumenal side of the closed channel is 
occupied by a short helix (TM2a) called the plug domain.
The translocon provides a dynamic interface between 
the water filled inside of the channel and the lipid environ-
ment. Hence, most eukaryotic membrane proteins with a 
(trans)membrane domain (such as a hydrophobic α-helix) 
are inserted into the ER membrane during co-translational 
translocation. In the current understanding of membrane 
integration, individual TM segments insert sequentially 
in the membrane layer through the lateral gate of Sec61 
[19]. Furthermore, the channel can accommodate several 
TM helices at the same time, and facilitates early folding 
of these segments before release into the membrane [20]. 
Multiple accessory factors are dynamically recruited to the 
translocon and assist the Sec channel (Fig. 1), e.g., through 
the chaperoning functions of translocon-associated protein 
(TRAP) and translocating chain-associated membrane pro-
tein (TRAM). Other factors associate with the translocon to 
perform post-translational modification of the peptide sub-
strates: oligosaccharyl–transferase (OST) complex facilitates 
N-linked glycosylation, while the SPC cleaves signal pep-
tides from the mature protein.
Non‑selective inhibition of RNC transfer 
to the translocon
The chemical compound eeyarestatin I (ESI) (Fig. 2) was 
discovered as an inhibitor of endoplasmic reticulum-associ-
ated protein degradation (ERAD) that induces an ER stress 
response in cells which leads to cytotoxicity [21]. ERAD 
removes misfolded proteins (and certain folded proteins) 
from the ER and plays a key role in ER homeostasis [22]. 
After recognition for ERAD, target proteins are modified by 
Fig. 1  Co-translational translocation in eukaryotes relies on SRP 
for targeting to the Sec61 translocon. Ribosomal protein synthesis is 
coupled to translocation, which protects the peptide and effectively 
uses the energy from chain elongation as a driving force. The chan-
nel also facilitates membrane integration of hydrophobic transmem-
brane domains (TMDs, dark blue box) through a lateral gate. Multi-
ple accessory factors reside in the local membrane environment and 
are dynamically recruited to assist the function of the translocon. 
The lumenal signal peptidase complex (SPC) cleaves signal pep-
tides (orange box) from the mature protein, while uncleaved signal 
anchors (yellow box) function as transmembrane domains in integral 
membrane proteins. Inhibitors of co-translational translocation are 
indicated in blue text and the targets are explained in more detail in 
Table 1
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E3 ubiquitin ligases, retrotranslocated towards the cytosol 
and finally degraded by the proteasome. ESI inhibits the 
action of p97/VCP, a cytosolic ATPase that extracts poly-
ubiquitinated ERAD substrates from the ER membrane [23]. 
ESI also interferes with co-translational protein import into 
the ER, as it blocks the transfer of a SP from the RNC-SRP 
complex into the Sec61 channel’s acceptor site [24]. This 
ESI-induced general block of protein translocation results 
in cytosolic accumulation of polyubiquitinated proteins 
and induces the unfolded protein response (UPR) [25]. The 
UPR normally protects the cell during ER stress, and is often 
upregulated in cancer cells. However, prolonged activation 
of UPR can induce cell death through apoptosis [26]. Con-
sequently, ESI can be considered as an anticancer agent. 
In addition, Aletrari et al. showed that ESI also interferes 
with vesicular trafficking of Shiga-like toxin, which uses 
endosomal vesicles to reach the ER lumen and then exploits 
the ERAD machinery to enter the cytosol through ER retro-
translocation [27].
Inhibitors of translocon gating
Mycolactone
The polyketide macrolide mycolactone (Fig. 2) is a virulence 
factor produced by the human pathogen Mycobacterium 
ulcerans and causes necrotizing lesions of the skin without 
acute inflammation [28]. Hall et al. showed that mycolac-
tone is a non-selective inhibitor of Sec61-dependent trans-
location across the ER [29]. Additionally, the inhibitory 
effect on cells was irreversible, indicative of a high affinity 
Fig. 2  Chemical structure of several natural and synthetic inhibitors 
of co-translational translocation. Eeyarestatin I blocks the transfer of 
a SP from the RNC–SRP complex to Sec61. Mycolactone induces 
a conformational change in the Sec61 channel. HUN-7293 and its 
derivatives cotransin and CAM741 interfere with signal peptide inser-
tion at the translocon. Decatransin and apratoxin A inhibit transloca-
tion into the ER lumen and can prevent growth of tumor cells. CADA 
prevents co-translational translocation of hCD4 and sortilin
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binding. The lack of immune response to this molecule is 
thus due to its suppression of inflammatory cytokine and 
receptor production in immune cells, and due to an indirect 
inhibition of antigen cross-presentation [30]. The eukary-
otic Sec61 channel was recently identified as the target of 
mycolactone. Chemical crosslinking data suggest that the 
compound induces a conformational change of the chan-
nel that significantly disturbs co-translational translocation 
efficiency, but has less impact on post-translational translo-
cation substrates [31].
Exotoxin A
The Pseudomonas aeruginosa protein exotoxin A is a cyto-
toxic ADP-ribosyltransferase that enters the eukaryotic cyto-
sol trough retrograde transport and inhibits retrograde export 
of immunogenic peptides from the ER towards the cytosol. It 
binds to Sec61α and prevents both co- and post-translational 
translocation [32, 33]. Exotoxin A also competes with cyto-
solic protein calmodulin (CaM) for binding to an N-terminal 
IQ motif on Sec61α and prevents  Ca2+ leakage through the 
channel in human cells [34]. These observations suggest that 
the protein keeps the Sec61 channel in a closed state.
Cotransins
A group of cyclic heptadepsipeptides are derived from the 
fungal macrocycle HUN-7293. The latter inhibits expression 
of three endothelial cell adhesion molecules: intercellular 
adhesion molecule 1 (ICAM-1), vascular cell adhesion mol-
ecule (VCAM-1) and E-selectin [35]. One derivative called 
cotransin (Fig. 2) was shown to inhibit the co-translational 
translocation of several proteins into the ER, in a signal pep-
tide-selective way [36]. These initial studies reported inhibi-
tion of VCAM-1, P-selectin, angiotensinogen, β-lactamase, 
and corticotropin-releasing factor receptor 1 (CRF-R-1). 
Later studies also identified endothelin B receptor [37], 
human epidermal growth factor receptor 3 [38] and tumor 
necrosis factor alpha (TNFα) [39], a type II integral mem-
brane protein with uncleaved signal anchor, as targets of 
cotransin.
Cotransin does not affect SRP recognition or targeting, 
but prevents access of NCs to the ER lumen, suggesting 
that the compound inhibits signal peptide-dependent gating 
of the Sec61 channel (Fig. 1). Accessory translocon factors 
such as TRAP, TRAM, Sec62/63 and binding immunoglobu-
lin protein (BiP) are not required for cotransin activity, as 
the compound was able to selectively prevent translocation 
of VCAM-1 in minimal proteoliposomes (containing only 
Sec61 and SR) [36]. Garrison et al. suggested that cotran-
sin either stabilizes the channel in a closed conformation or 
that it allosterically alters the signal peptide binding site of 
Sec61. These hypotheses, respectively, restrict productive 
interaction of low-affinity SPs or decrease the SP binding 
site flexibility, which both result in substrate selection at 
the translocon.
It must be noted that the reported compound concentra-
tions used in the different translocation assays varies widely, 
which is important for the interpretation of the selectivity 
concept. For example, cotransin operates selectively at low 
nanomolar concentrations [36]. In contrast, Klein et al. have 
recently shown that a saturating concentration of cotransin 
(30 µM) actually inhibits translocation of a broad range of 
secreted proteins, while integral membrane proteins are 
mostly unaffected [40].
Decatransin
Decatransin is a fungal cyclic decadepsipeptide (Fig. 2) that 
prevents growth of human carcinoma cells [41]. It is syn-
thesized by a non-ribosomal peptide synthetase. Such very 
large modular enzymes are often used by microorganisms to 
produce complex secondary metabolites [42]. Decatransin 
prevents Sec61/SecY-dependent co- and post-translational 
translocation into the ER lumen but does not affect SRP 
recognition or SR targeting [41].
Apratoxin A
Apratoxins are natural secondary metabolites isolated from 
a marine cyanobacterium. They are also produced by a non-
ribosomal peptide synthetase [43]. The cyclic depsipeptide 
apratoxin A (Fig. 2) was discovered as a cytotoxic antitumor 
drug and prevents growth of various cancer cell lines by 
inducing G1 cell cycle arrest and apoptosis [43, 44]. Prot-
eomic data showed that expression of a subset of secreted 
and membrane proteins are downregulated by apratoxin A, 
and this effect was due to an inhibition of their co-transla-
tional translocation [45].
Gating inhibitors likely operate 
through a common mechanism
Mutations in Sec61 provide cross‑resistance 
to gating inhibitors
Photo-crosslinking experiments showed that HUN-7293 
derivatives bind to the Sec61α subunit [46], as predicted ear-
lier. A more recent study used genetic selection in the DNA 
repair-defective HCT-116 tumor cell line to identify muta-
tions that confer cotransin resistance [47]. These mutations, 
located in a region near the lateral gate and plug domain of 
Sec61α, stabilize the plug domain in the closed state and 
allosterically prevent the translocation substrate from open-
ing the channel (Fig. 3). Extensive crosslinking experiments 
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showed that the arrested transmembrane domain (TMD) of 
TNFα is positioned at the interface of Sec61alpha helices 2 
and 7, perpendicular to the channel helices. However, TMDs 
with increased hydrophobicity or helical propensity are able 
to escape the cotransin-induced block [47].
Accordingly, resistance mutations for apratoxin A were 
all located near the Sec61 plug domain and several of these 
mutations confer cross-resistance against cotransin [48]. 
Apratoxin A also competes with cotransin for translocon 
binding, suggesting a mutually exclusive binding site near 
the lumenal plug region. Compared to cotransin, apratoxin A 
does not arrest the TNFα TMD in a preferred orientation on 
the cytosolic side of Sec61. This suggests that the compound 
blocks TNFα translocation in an earlier step, before TMD 
insertion occurs [48].
Decatransin might act similar to cotransin, as several (but 
not all) mutations in Sec61 that provide resistance to cotran-
sin also confer decatransin resistance. Additionally, both 
decatransin and CP2, a compound very similar to HUN-
7293/cotransin, inhibit translocation in yeast Sec61α and 
bacterial SecY [41], suggesting that the translocon might 
contain a universal binding site for natural translocation 
inhibitors. Junne et al. hypothesized that these hydrophobic, 
peptide-like molecules mimic signal peptides and can bind 
to the Sec translocon, where they block incoming peptides 
and stabilize the closed translocon conformation [41].
Fig. 3  Location of the mutations in mammalian Sec61 that confer 
resistance to different gating inhibitors. Cryo-electron microscopy 
model of mammalian Sec61 from Protein Data Bank accession code 
3J7Q [52]. The lateral gate (TM 2 and 7) is shown in blue and the 
plug helix in orange. The loop that connects TM 3 and 4 contains 
M136 but was not resolved in the model and is inferred from the 
Archaeal SecY structure (PDB 1RHZ) [8]
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Mycolactone showed a broad effect not only on co-trans-
lational translocation but also dose-dependently competed 
with a cotransin variant (CT7) for translocon binding sug-
gesting that they likely share a binding site [49]. When tested 
for cross-resistance in the cotransin-resistant cell lines, sev-
eral mutations near the lumenal plug indeed provided myco-
lactone resistance (Fig. 3).
Gating inhibitors stabilize the translocon in a closed 
state
The prl (protein localization) phenotype of bacteria and 
yeast, characterized by the ability to translocate defective 
signal peptides, has historically been associated with muta-
tions in the translocon plug and pore ring, as these mutations 
destabilize the closed translocon conformation [50, 51]. 
Interestingly, the observed resistance mutations for HUN-
7293 derivatives, decatransin, apratoxin and mycolactone 
also map to residues located on the lumenal side of the trans-
locon lateral gate, near the plug domain and thus resemble 
the prl phenotype. The resistance mutations are believed to 
increase the flexibility of the translocon, which overrules 
the action of the inhibitors, i.e., keeping the translocon in a 
closed state [41]. Paatero et al. suggested that these natural 
and synthetic compounds all target a similar binding site 
on the Sec61α translocon to regulate translocation (Fig. 3). 
Due to significant differences in their chemical structure and 
potency though, each of these natural compounds produces 
a distinct inhibitory profile [48].
Since the translocon machinery evolved to accept a broad 
range of targeting signals, it is surprising to see a selective 
inhibition of only a small subset of translocation substrates 
for some of the inhibitors. Nevertheless, such a selective 
suppression of cell surface receptor expression can have 
many novel therapeutic and antiviral applications. Hegde 
and Kang proposed that, in absence of accessory translocon 
components, the interaction between Sec61 and most signal 
peptides is intrinsically unstable [53]. Only a limited set of 
‘strong’ sequences are able to engage the channel on their 
own, for a sufficiently long duration to allow for complete 
insertion of the elongating chain, and subsequent translo-
cation of the protein. All other targeting signals (‘weak’ 
sequences) are assumed to have a very low basal translo-
cation efficiency. In this model, the occurrence of many 
Sec61-associated protein complexes (e.g., TRAP, TRAM, 
Sec62/63, BiP and OST) that dynamically assist the trans-
locon, is the key concept that regulates substrate-specific 
translocation efficiency. Selective inhibition of translocation 
is possible too, either through (allosteric) destabilization of 
channel/signal peptide interactions or through stabilization 
of the translocon channel in a closed state. Additional regu-
latory factors likely exist, as the current knowledge is mostly 
obtained from a very limited set of model translocation 
systems (e.g., dog pancreas cells, model yeast and bacte-
rial systems). Properties of Sec-dependent signal peptides 
are thus linked to the observed variation in selectivity (the 
inhibitory profiles) of these gating inhibitors.
Selective inhibition of signal peptide 
topology inversion
The small molecule cyclotriazadisulfonamide (CADA) is a 
synthetic macrocycle (Fig. 2) that showed antiviral activ-
ity against a broad range of human immunodeficiency virus 
(HIV) strains and human herpes virus-7 (HHV-7). Analysis 
of receptor expression showed that CADA treatment induced 
a downregulation of the cell surface- and intracellular CD4 
levels. Since both HIV and HHV-7 use CD4 as the primary 
receptor for cell entry, this down-modulation of CD4 is 
responsible for CADA’s inhibition of viral entry [54].
CADA selectively inhibits the cell surface expression 
of human CD4 (hCD4) on a post-transcriptional level. The 
compound interacts with the signal peptide of hCD4 and 
it prevents co-translational translocation of the pre-protein 
chain across the ER membrane [55]. Instead, the affected 
precursor protein chains end up in the cytosol where they 
are degraded by the proteasome. Targeting of RNCs to the 
ER translocon is not affected by the compound. The hCD4 
signal peptide initially inserts head-on  (Nexo/Ccyt) into the 
translocon, and inverts to a looped topology  (Ncyt/Cexo) 
upon chain elongation (transitioning, Fig. 1). Early models 
assumed that signal peptides generally insert into the trans-
locon with a looped topology, but head-on insertion and a 
dynamic topology inversion has been described for signal 
anchor proteins [56, 57]. Vermeire et al. suggest that CADA 
interferes with the mandatory inversion (transitioning) of 
hCD4’s signal peptide, and thereby prevents translocation 
of the chain.
Furthermore, the down-modulating effect of CADA 
seems to be selective for hCD4 and the membrane glyco-
protein sortilin. As previously shown for hCD4, CADA 
also inhibits the co-translational translocation of sortilin in 
a signal peptide-dependent way [58]. The effects of CADA 
on sortilin were less pronounced as compared to hCD4 
though, and sortilin appears to be a secondary substrate of 
CADA. Importantly, expression of the homologous mouse 
CD4 protein is not affected by CADA. Mutagenesis of the 
CD4 signal peptide identified the central hydrophobic signal 
peptide region as crucial for CADA sensitivity, with a lesser 
contribution from the C-terminal SP region [55].
The binding site of CADA is not known, but quantitative 
structure–activity relationship studies of CADA analogues 
suggest a two-site binding model for these compounds [59, 
60], and surface plasmon resonance experiments showed a 
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selective, non-covalent interaction between CADA and the 
human CD4 signal peptide [55].
Another HUN-7293 derivative, CAM741 (Fig. 2), also 
interferes with the co-translational translocation of only a 
limited set of substrates in a signal peptide-selective way. 
VCAM-1 [61, 62] and VEGF [63] are reported CAM741 
targets. Blocked polypeptide chains are directed towards 
the cytosol and degraded by the proteasome [36, 61]. Their 
cytosolic accumulation also induces the unfolded protein 
response [25]. The compound CAM741 prevents correct 
insertion of the VCAM-1 SP into the translocon [62]. Using 
a diagnostic amino-terminal glycosylation tag, the topology 
of the VCAM-1 SP was determined during the early post-
targeting phase: it initially inserts head-on  (Nexo/Ccyt) into 
the translocon channel and reorients upon polypeptide chain 
elongation. However, the amino-terminus does not enter the 
ER lumen in the presence of CAM741. Systematic analysis 
of VCAM-1 signal peptide mutants identified residues in the 
SP C-region, h-region and the first residue of the VCAM-1 
mature domain as crucial elements for full CAM741 sensi-
tivity [62]. VEGF-1 mutagenesis revealed a different pattern, 
as mutagenesis of leucines in the N-terminal SP region and 
hydrophobic residues in the h-region resulted in a loss of 
compound sensitivity [63].
Signal peptides with increased hydrophobicity are able 
to escape CAM741 activity, while reducing the hydropho-
bicity of VCAM-1 and VEGF-1 SP’s h-region increases 
the inhibitory effect of CAM741 and vice versa [62, 63]. 
Hydrophobicity is a major determinant of TM segment rec-
ognition at the translocon [64], and signal peptide recog-
nition at the translocon is also dependent on hydrophobic 
interactions. Targeting signals were shown to interact with 
a specific hydrophobic patch on the cytosolic side of Sec61, 
after which they intercalate between the channel helices 
[18]. Mutations in the signal peptide that increase its hydro-
phobicity are thus better at opening the channel (they are 
“stronger” signal peptides according to Hegde’s theorem of 
translational regulation [53]) and this should allow them to 
overcome the translocational block imposed by CAM741 
more easily.
SRP‑independent translocation
After more than 30  years of study, it is clear that SRP-
dependent co-translational translocation is highly efficient. 
However, it is now also evident that a significant fraction 
of all ER-targeted proteins do not utilize the SRP pathway 
for targeting, and/or do not even rely on the Sec61 translo-
con for translocation [65–67]. Membrane proteins with large 
translocated domains or multiple TM domains are usually 
constrained to the SRP-dependent co-translational pathway, 
but other physical limitations can restrict SRP recognition. In 
bacteria and yeast, SRP recognition requires targeting signals 
with sufficiently high hydrophobicity. SPs with low or moder-
ate hydrophobicity are targeted towards the Sec61-dependent 
post-translational pathway [68]. Mammalian SRP does not 
differentiate between SPs of different hydrophobicity, while 
microorganisms likely favor post-translational translocation to 
support higher rates of protein secretion, as this pathway does 
not use up the limited pool of ribosomes [69].
These SRP-independent polypeptides must often be kept in 
a translocation-competent state during the targeting towards 
the translocon. The translocon pore is quite narrow and only 
allows passage of proteins with limited secondary structure. 
Therefore, excessive folding or aggregation of pre-proteins 
must be prevented (Fig. 4). Multiple cytosolic proteins, e.g., 
heat shock protein 70 (Hsp70) and Hsp40 chaperones, assist 
this process after completion of translation [70]. Hsp70 s bind 
to exposed hydrophobic protein regions in an ATP-dependent 
way, while their ATPase activity is regulated by Hsp40 co-
chaperones. It is still unclear which factors target these chap-
erones towards the ER [66].
Another one of these cytosolic factors is the calcium-bind-
ing protein calmodulin, that was shown to maintain the small 
protein preprocecropin A (64 amino acids) in a translocation-
competent state inside the cytosol, by selective binding to the 
signal peptide [71]. CaM also binds to the cytosolic N termi-
nus of Sec61α, which is proposed as the targeting mechanism 
for these peptides.
Chaperone inhibitors
NSC 630668‑R/1
In a screen for heat shock cognate 70 (Hsc70, a member of 
the Hsp70 chaperone family)-interacting compounds, NSC 
630668-R/1 (referred to as R/1) was identified as an inhibi-
tor of Hsc70 ATPase activity (Fig. 4). R/1 almost completely 
inhibits in vitro post-translational translocation of pre-pro-
α-factor (ppαF) in yeast microsomes at a concentration of 
300 µM, with an  IC50 of 6 µM [72].
Calmodulin inhibitors
Ophiobolin A and E6 Berbamine are specific antagonists of 
CaM, and thus disrupt the translocation competence of small-
secreted proteins (SSPs) that depend on CaM during the target-
ing phase towards the ER [71].
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Driving forces in post‑translational 
translocation
The polymerization of peptides in the ribosome provides 
a directional driving force during co-translational trans-
lation. GTP is hydrolyzed during the ribosomal chain 
elongation step, which pushes the preprotein through the 
ribosomal exit tunnel and translocon pore [73] (Fig. 1). 
However, roughly 70 residues still remain inside the tun-
nel and channel after completion of translation [74] and 
this chain can move freely up and down through the chan-
nel. Cells employ a secondary mechanism to complete the 
translocation of this free-moving substrate: after sufficient 
downwards diffusion (due to Brownian motion) of the 
chain through Sec61 and towards the lumen, the chaperone 
BiP can bind to the exposed chain segment. Once bound 
to BiP, the chain segment cannot diffuse back to the cyto-
solic side. This starts a cycle, where stepwise binding of 
additional BiP molecules acts as a ‘molecular ratchet’ that 
pulls nascent chains towards the lumen [75, 76] (Fig. 1).
Sec61-dependent post-translational translocation (Fig. 4) 
requires the Sec62/63 complex and the lumenal BiP chaper-
one for directional protein movement through the translocon 
channel towards the lumen [77], similar to the function of 
BiP in co-translational translocation. Sec62 is an integral 
membrane protein that forms a stable complex with Sec63 
and associates with ER-bound ribosomes, where it binds 
near the ribosomal exit tunnel [78] (Fig. 1). These proteins 
are highly abundant in the mammalian ER [79]. A study 
by Reithinger et al. used the yeast model system to show 
that Sec62 is required in addition to SRP for the targeting 
and translocation of uncleaved signal anchor sequences with 
moderate hydrophobicity [80]. Sec62 is also required for 
post-translational translocation of SSPs, an important class 
of SRP-independent proteins [77]. Due to their small size 
(< 160 aa), the signal peptide of these SSPs remains (par-
tially) buried inside the ribosomal exit tunnel after comple-
tion of translation, which prevents recognition by SRP [81]. 
Additionally, Sec62 is suggested to function as a receptor 
that detects  Ca2+ leakage through Sec61 and facilitates CaM 
recruitment [82], which in turn mediates  Ca2+-dependent 
Fig. 4  Sec-dependent post-translational translocation of pre-proteins 
involves several chaperone proteins. a Calmodulin binds signal pep-
tides (orange box) and is targeted to Sec61, as Sec61 contains a cyto-
solic signal peptide-binding site. Hsp chaperones retain cytosolic pro-
teins in a translocation-competent state and are targeted to Sec62/63. 
Other chaperone-independent targeting pathways are possible too, 
e.g., with intrinsically disordered proteins. The J domain of Sec63 
converts BiP to a state with high affinity for protein binding. Sequen-
tial binding of BiP molecules works as a ratcheting mechanism that 
drives post-translational translocation. b Targeting of bacterial pre-
proteins can occur either in a chaperone-dependent way through the 
help of SecA, SecB or trigger factor (TF), or in a chaperone-inde-
pendent way. SecY-dependent post-translational translocation in bac-
teria relies on the essential ATPase motor protein SecA and the pro-
ton motive force (PMF) to drive translocation of pre-proteins through 
the SecY pore and across the plasma membrane. Inhibitors of translo-
cation are indicated in blue text
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closure of the channel [83]. Interestingly, the different func-
tional studies and the location of Sec62 near the ribosome 
suggests that both (co- and post-) translocational systems 
overlap at this site.
The BiP chaperone has multiple functions 
during both co‑ and post‑translational translocation
ER-resident Hsp40/DnaJ-like proteins ERdj1 and Sec63 
(ERdj2) are integral membrane proteins that recruit the 
lumenal Hsp70 member BiP (termed Kar2p in yeast) to 
the translocon (Figs. 1, 4a) [77, 84–86]. BiP consists of a 
substrate binding domain and a nucleotide-binding domain 
and can perform several functions during protein transloca-
tion: (1) BiP is proposed to drive translocon gating from the 
closed to the open state during early stages of translocation, 
as it was found to assist with insertion of precursor peptides 
into the channel [87]. The chaperone can bind to loop 7 of 
Sec61α, which forms the hinge region between both halves 
of the channel, and this binding energy facilitates insertion 
of ‘weak’ nascent peptides which are otherwise unable to 
open the channel by themselves [7, 88]. (2) It closes off the 
lumenal side of Sec61 and returns the channel to a closed 
state to prevent  Ca2+ efflux after translocation has ended [88, 
89]. (3) BiP acts as a molecular ratchet to complete trans-
location of pre-proteins in both co- and post-translational 
Sec61-dependent translocation (Figs. 1, 4a) [76, 90]. The 
substrate-binding domain of BiP has affinity for unfolded 
hydrophobic oligopeptides [91] and this affinity is regulated 
by its nucleotide-binding domain. The ATP-bound state of 
BiP has low substrate affinity while the ADP-bound state has 
high affinity [92]. Recruitment of BiP to the translocon com-
plex allows Sec63 and ERdj1 to activate BiP’s ATPase activ-
ity with their lumenal J domain. This converts the bound 
ATP to ADP and thus increases the substrate binding affin-
ity, which allows BiP to bind peptides as they emerge from 
the translocon. After completion of translocation, release of 
bound proteins from BiP requires exchange of ADP for ATP, 
which is performed by two lumenal nucleotide exchange fac-
tors: Grp170 and Sil1 [92].
SecA‑dependent post‑translational translocation
Bacteria (and chloroplasts in plants) uniquely contain SecA 
as part of their translocation systems. SecA recognizes tar-
geting signals in cytoplasmic pre-proteins and functions as 
an essential motor protein that mechanically drives post-
translational translocation, as it uses sequential cycles of 
substrate clamping and ATP-dependent domain movement 
to push the preprotein through the SecYEG channel [14, 
93]. Interestingly, mature protein regions are also bound to 
a (currently unknown) site on SecA and can target the pre-
protein independent of their signal peptide, but this only 
occurs after allosteric activation of SecA by a bound signal 
peptide [94, 95].
Inhibition of the translocational driving 
force
Mycolactone
In addition to the previously described actions, mycolactone 
also depletes BiP and this may affect the translocation of 
other proteins indirectly [49]. Co-translational translocation 
of BiP itself could be inhibited by mycolactone too, result-
ing in lower luminal BiP levels, and further amplifying the 
inhibition of translocation for BiP-dependent substrates.
Valinomycin
The macrocycle valinomycin, isolated from an Actinomycete 
culture, is a known potassium anionophore [96]. Interest-
ingly, it was identified as a down-regulator of BiP expression 
and induces cell death in cancer cells with glucose starva-
tion [97]. The chaperone function of BiP protects cells dur-
ing ER stress and supports the unfolded protein response. 
Reduced BiP levels in valinomycin-treated cancer cells can 
thus result in cell death under ER stress conditions, which 
are typical for solid tumor environments where nutrient sup-
ply is limited due to the poor vascularization. Valinomycin 
is also a signal peptide-specific inhibitor of hamster prion 
protein (PrP) translocation [98]. Inefficient translocation of 
PrP leads to cytosolic accumulation and misfolding of the 
protein, resulting in cytotoxic protein aggregates. Interest-
ingly, human PrP was not affected by valinomycin and this 
selectivity was due to small differences in the signal peptides 
of these two homologous proteins. The downregulation of 
BiP is suggested as a mechanism for the selectivity of the 
compound, as BiP dependency is linked to targeting prop-
erties of the signal peptide: ‘weak’ signal peptides require 
assistance from accessory factors for translocon gating, 
which is one of the proposed functions of BiP.
R/1 derivatives
Two derivatives of R/1, MAL3-39 and MAL3-101, were 
shown to inhibit the in vitro post-translational translocation 
of ppαF substrates, but these derivatives are less active and 
only inhibit, respectively, 45 and 30% of translocation at 
300 µM [99]. While R/1 affects both the innate and Hsp40-
stimulated ATPase activity of Hsp70 chaperones, MAL3-39 
and MAL3-101 only inhibit the J domain-mediated stimu-
lation of Hsp70 ATPase activity. It is suggested that these 
two derivatives enter the ER lumen, where they modulate 
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the functions of BiP/Kar2p and Sec63, and therefore, affect 
post-translational translocation.
Bactericidal ATPase inhibitors
In bacteria, most secretory and membrane proteins (~ 95% 
in Escherichia coli) rely on the highly conserved Sec path-
way for their membrane insertion or translocation across the 
plasma membrane [100]. SecA is essential for SecY-depend-
ent post-translational translocation in bacteria (Fig. 4b), but 
it is absent in eukaryotes, which makes this an attractive tar-
get for the development of new antibacterial drugs (Table 1).
CJ-21058, a derivative of the fungal antibiotic equisetin 
was discovered as the first inhibitor of E. coli SecA ATPase 
activity [101]. It also showed antibacterial activity against 
multidrug-resistant Staphylococcus aureus and Entero-
coccus faecalis. The fluorescein analogs rose Bengal and 
erythrosin B are able to inhibit the in vitro translocation of 
proOmpA through inhibition of the SecA ATPase activity. 
These compounds are predicted to occupy the ATP binding 
site in SecA [102]. Inhibition of ATPase activity was indeed 
competitive at low ATP concentrations, however, more 
recent data shows that rose bengal non-competitively inhib-
its the translocation activity of SecA at high ATP concentra-
tions [103]. They have both bacteriostatic and bactericidal 
effects. Five compounds (termed P97-A9 family in Fig. 4) 
were identified in a small molecule screening as inhibitors 
of SecA translocase activity [104]. These compounds target 
the signal peptide binding site in SecA, a conserved and 
essential feature in SecA from both Gram positive and Gram 
negative bacterial species, and also showed weak antimicro-
bial activity. Recently discovered analogues of bisthiouracil 
[105, 106] and the bistriazole compound SCA-21 [107] are 
more potent inhibitors of the ATPase activity and SecA-
dependent protein translocation. Moreover, they are effective 
against methicillin-resistant S. aureus strains. For most of 
these SecA inhibitors, permeability of the outer membrane 
in Gram negative bacteria was required for the antimicro-
bial activity [108]. These novel antibacterial mechanisms 
are promising solutions for the urgent problem of multidrug-
resistant pathogens.
Alternative targeting pathways
Tail‑anchored proteins
Due to their structure, TA proteins should not be able to 
use the SRP-driven targeting system, as their C-termi-
nal targeting signal remains hidden inside the ribosome 
during protein synthesis (Fig. 5). Instead, they rely on the 
Bag6/SGTA complex (or Sgt2 in yeast) and a completely 
different set of proteins termed transmembrane domain 
recognition complexes (TRCs) for recognition and tar-
geting to the ER membrane receptors WRB and CAML. 
These protein complexes then facilitate membrane inser-
tion independent of Sec61 [109]. The yeast ortholog of 
TRC is GET; “guided entry of tail-anchored proteins”.
SRP‑independent targeting
A route that functions in parallel with the SRP and TA 
pathways, termed SND (SRP-independent targeting), was 
recently discovered in Saccharomyces cerevisiae [110, 
111]. Three proteins were identified (Fig.  5): Snd1 is 
located in the cytosol and predicted to interact with the 
ribosome, where it may act as the receptor for hydrophobic 
targeting signals. Snd2 and Snd3 form a complex in the 
ER membrane, together with the translocon, and could act 
as targeting receptors. Though only described in yeast, a 
human ortholog of Snd2 exists (hSnd2) and its function as 
a membrane receptor was recently confirmed [112]. The 
SND pathway was originally shown to serve as a backup 
targeting system for both SRP-dependent and TRC40-
dependent pathways in yeast [110]. Recent evidence also 
showed that the TRC40 targeting pathway is not essential 
for integration of TA proteins in human cells, as membrane 
integration of TA proteins in TRC40 knockouts can be 
complemented by both the SND and SRP pathways [113]. 
This supports the idea that SRP is likely able to recognize 
some targeting signals inside the ribosomal exit tunnel, 
near the end of TA protein translation, instead of outside 
the ribosome [114–116].
Inhibitors of the TRC40 pathway
Calmodulin inhibits ER membrane insertion of mammalian 
TA proteins in multiple translocation pathways, likely due to 
binding of CaM to the targeting signals as in Sec-dependent 
post-translational translocation, masking them for recogni-
tion. This function of CaM has been suggested as a regula-
tory mechanism for the TRC40 pathway [117].
TRC40 is also involved in ER targeting of SSPs [118] 
and glycosylphosphatidylinositol (GPI)-anchored proteins 
[66]. Targeting of these proteins is thus apparently facili-
tated by multiple SRP-independent pathways. Mycolactone 
is an interesting inhibitor in this regard because it only par-
tially affects translocation of SSPs. Some SSP pre-proteins 
that normally use the Sec61 pathway are able to escape the 
translocational block; in the presence of mycolactone, they 
are redirected to alternative pathways such as the TRC40 
pathway. Importantly, hydrophobicity of the signal peptide 
and properties of the mature domain were shown to affect 
mycolactone sensitivity of SSPs [31].
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Table 1  Overview of different inhibitors and modulators of translocation
Inhibitor Target Affected translocation pathways
Virulence factors and retrograde transport inhibitors
 Eeyarestatin I Prevents NC transfer from SRP to Sec61 [24]
Binds p97 ATPase [23, 126]
Sec61-dependent co-translocational import [24]
ER-associated protein degradation [23, 127]
Induces UPR [25]
 Mycolactone Induces an irreversible conformational change 
in Sec61α [31]
Broad effect on Sec61-dependent co-transla-
tional translocation, selective inhibition of 
Sec61-dependent post-translational transloca-
tion. SSPs are less affected. [29]
 Exotoxin A Modulates translocon gating, binds IQ motif 
on Sec61α N terminus, similar to CaM [33, 
34]
ER retrotranslocation of immunogenic peptides 
[32]
Chaperone inhibitors
 NSC 630668-R/1 Hsp70 ATPase inhibitor (BiP/Kar2p) [72] Post-translational translocation in yeast ER [72]
 MAL3-39 J domain-mediated Hsp70 ATPase activity 
[99]
Post-translational translocation in yeast ER [99]
 MAL3-101 J domain-mediated Hsp70 ATPase activity 
[99]
Post-translational translocation in yeast ER [99]
VSG_117 transport into Trypanosoma brucei 
ER [119]
 E6 Berbamine Calmodulin antagonist [128] Calmodulin-dependent post-translational trans-
location of small proteins [71]
 Ophiobolin A Calmodulin antagonist [129] Calmodulin-dependent post-translational trans-
location of small proteins [71]
SecA inhibitors
 Equisetin and CJ-21058 SecA ATPase inhibitor [101] SecA-dependent post-translational translocation 
[101]
VSG_117 transport into Trypanosoma brucei 
ER [119]
 Rose bengal and erythrosin B SecA ATPase inhibitor [102] SecA-dependent post-translational translocation 
[102]
 P97-A4, P87-A4, 17D9, P91-E9, 16F6 Inhibits signal peptide binding to SecA [104] SecA-dependent post-translational translocation 
[104]
 Bisthiouracil SecA ATPase inhibitor [105, 106] SecA-dependent post-translational translocation 
[105, 106]
 SCA-21 SecA ATPase inhibitor [107] SecA-dependent post-translational translocation 
[107]
Cyclic depsipeptides and triaza compounds
 HUN-7293 Traps NC TMDs at the cytosolic side of the 
Sec61α lateral gate [47]
ICAM-1 and VCAM-1 translocation [35]
 Cotransin Traps NC TMDs at the cytosolic side of the 
Sec61α lateral gate [47]
Signal-peptide-specific inhibition of ER translo-
cation: VCAM-1, P-selectin, angiotensinogen, 
β-lactamase, CRF-R-1 [36], endothelin B 
receptor [37], TNFα [39], HER3 [38]
Affects most secreted proteins, but only a 
minority of integral membrane proteins [40]
 CAM741 Prevents correct insertion of VCAM-1 NCs 
into the translocon [62]
VCAM-1 [61] and VEGF [63] translocation
 Apratoxin A Stabilizes the Sec61α in a closed conforma-
tion [48]
Selective inhibition of co-translational translo-
cation [45]
Broad-spectrum inhibition of translocation [48]
 Decatransin Targets Sec61/SecY, similar but not identical 
to cotransin [41]
Sec-dependent co- and post-translational trans-
location [41]
 Valinomycin K+ anionophore [96]
Down-regulates BiP [97]
Signal-peptide-specific inhibitor of hamster PrP 
translocation [98]
 CADA Interferes with SP topology inversion inside 
the Sec61 translocon [54]
Co-translational translocation of human CD4 
[54] and sortilin [58]
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Species‑specific signal peptides
The GPI-anchored surface protein VSG_117 protein from 
Trypanosoma brucei, a protozoan parasite responsible 
for human African trypanosomiasis (sleeping sickness), 
is used for immune evasion in the bloodstream. Inter-
estingly, post-translational translocation of VSG_117 is 
inhibited by MAL3-101, equisetin and CJ-21058 [119], 
three ATPase-related inhibitors (Table 1).
Trypanosomatida diverged early from other eukaryotes 
and they developed a surprisingly different SRP complex 
[120]. Importantly, T. brucei signal peptides are incompat-
ible with the eukaryotic post-translational translocation 
pathway [121]. Properties of the hydrophobic region of the 
targeting signals appear to determine compatibility with 
the mammalian translocation system, likely due to their 
different interactions with the unique trypanosomal SRP. 
Most trypanosomal signal peptides are also able to use 
multiple translocation pathways, but they depend heavily 
on the SRP-independent post-translational translocation 
pathway for the production of their GPI-anchored proteins. 
Sec71, a non-essential post-translational translocon com-
ponent in yeast which is not present in mammalian cells, 
is also present in T. brucei and essential for their survival 
[122].
Compounds like MAL3-101 might, therefore, offer a 
novel method for the treatment of trypanosomal infection. 
Selective inhibition of only trypanosomal post-translational 
translocation is possible due to the differences in the com-
position of host and parasite signal peptides and the corre-
sponding translocon complexes. This key therapeutic con-
cept of signal peptide-selective translocation inhibition was 
previously demonstrated in mammalian cells for the HUN-
7293/cotransin family and CADA compounds (Table 1).
Conclusions
Since the discovery of the ubiquitous Sec-dependent protein 
translocation pathway, various translocation inhibitors have 
been discovered (Table 1). Furthermore, recent reports have 
uncovered a significant redundancy between the different 
protein translocation pathways, in which properties of the 
targeting signals determine the preference for the selected 
translocation system. In this review, we highlighted how 
multiple stages in the different translocation pathways can 
be modulated or even inhibited, leading to either selective or 
broad inhibition of protein translocation. In general, most of 
the translocation inhibitors described here affect the recogni-
tion, chaperoning or function of the signal peptides.
Fig. 5  Alternative targeting pathways for translocation. a Tail-
anchored proteins have a single transmembrane domain at their C 
terminus that also acts as a targeting signal (purple box). A pretarget-
ing complex captures these C-terminal signals after release from the 
ribosome and transfers them to TRC40 (or Get3 in yeast) for target-
ing to the membrane receptor WRB/CAML (Get1/Get2 in yeast). The 
targeting factor TRC40 operates as a dimer and requires ATP to tran-
sition between open and closed states. Inhibitors of translocation are 
indicated in blue text. b The SRP-independent (SND) pathway serves 
as a backup system for the classical Sec61 and TRC40 targeting path-
ways. The membrane proteins Snd2 and Snd3 function as targeting 
receptors for Snd1
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Based on the characteristic inhibitory profile of each 
translocation inhibitor, there is some optimism that mod-
ulation of protein translocation can be exploited for the 
development of new therapeutic and antimicrobial applica-
tions. Recent CRISPR/Cas9-based screenings of host factors 
involved in viral replication revealed an important role of 
translocon-associated components [123, 124]. For cotransin, 
it has already been shown that it limits proteostasis of envel-
oped viruses such as influenza virus, human immunodefi-
ciency virus and dengue virus [125]. In addition for mycol-
actone, one might expect a similar broad antiviral effect as it 
influences translocation of a broad range of proteins. Screen-
ing for translocation inhibitors has resulted in the discovery 
of eeyarestatin I and apratoxin A with anticancer properties, 
and a new class of broad-spectrum antibacterial compounds 
is being developed based on inhibition of SecA. Notwith-
standing the long road to go for translocation inhibitors to 
become therapeutics, in the mean time they are valuable as 
research tools to decipher the remaining mysteries of protein 
translocation across membranes.
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